Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) Stock Competitors & Peer Comparison
See AMPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMPH | $26.86 | +2.79% | 1.2B | 9.35 | $2.93 | N/A |
| TAK | $18.52 | -1.83% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $39.90 | +1.81% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.01 | -2.75% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $70.47 | -0.82% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $17.91 | +0.45% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.42 | +0.49% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.89 | +5.18% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AMPH vs TAK Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TAK trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TAK's P/E ratio is 13.59. In terms of profitability, AMPH's ROE is +0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AMPH is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AMPH vs TEVA Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TEVA trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TEVA's P/E ratio is 13.27. In terms of profitability, AMPH's ROE is +0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AMPH is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TEVA's competition here
Haleon plc (NYSE: HLN)
AMPH vs HLN Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while HLN trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas HLN's P/E ratio is 18.78. In terms of profitability, AMPH's ROE is +0.10%, compared to HLN's ROE of +0.17%. Regarding short-term risk, AMPH is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
AMPH vs ZTS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ZTS trades at $70.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ZTS's P/E ratio is 10.85. In terms of profitability, AMPH's ROE is +0.10%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AMPH is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
AMPH vs VTRS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while VTRS trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas VTRS's P/E ratio is 7.25. In terms of profitability, AMPH's ROE is +0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AMPH is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AMPH vs ITCI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AMPH's ROE is +0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AMPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
AMPH vs CTLT Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AMPH's ROE is +0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AMPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AMPH vs ELAN Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ELAN trades at $22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ELAN's P/E ratio is 21.17. In terms of profitability, AMPH's ROE is +0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AMPH is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AMPH vs RDY Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while RDY trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas RDY's P/E ratio is 20.52. In terms of profitability, AMPH's ROE is +0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AMPH is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
AMPH vs ALKS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ALKS trades at $40.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ALKS's P/E ratio is 42.26. In terms of profitability, AMPH's ROE is +0.10%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, AMPH is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
AMPH vs AMRX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while AMRX trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas AMRX's P/E ratio is 22.78. In terms of profitability, AMPH's ROE is +0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, AMPH is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AMPH vs LNTH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while LNTH trades at $99.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas LNTH's P/E ratio is 16.76. In terms of profitability, AMPH's ROE is +0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AMPH is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AMPH vs INDV Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while INDV trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas INDV's P/E ratio is 10.10. In terms of profitability, AMPH's ROE is +0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AMPH is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
AMPH vs ALVOW Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, AMPH's ROE is +0.10%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, AMPH is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AMPH vs RGC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while RGC trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas RGC's P/E ratio is -436.62. In terms of profitability, AMPH's ROE is +0.10%, compared to RGC's ROE of -2.32%. Regarding short-term risk, AMPH is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AMPH vs SUPN Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SUPN trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SUPN's P/E ratio is 14.58. In terms of profitability, AMPH's ROE is +0.10%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AMPH is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AMPH vs HCM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while HCM trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas HCM's P/E ratio is 5.30. In terms of profitability, AMPH's ROE is +0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AMPH is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AMPH vs DCPH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AMPH's ROE is +0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AMPH is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AMPH vs BHC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while BHC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas BHC's P/E ratio is 1.47. In terms of profitability, AMPH's ROE is +0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AMPH is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AMPH vs AVDL Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AMPH's ROE is +0.10%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, AMPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
AMPH vs TRLV Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TRLV trades at $12.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TRLV's P/E ratio is -5.02. In terms of profitability, AMPH's ROE is +0.10%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, AMPH is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
AMPH vs PRGO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PRGO trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PRGO's P/E ratio is 6.03. In terms of profitability, AMPH's ROE is +0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AMPH is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
AMPH vs ALVO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ALVO trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ALVO's P/E ratio is -10.42. In terms of profitability, AMPH's ROE is +0.10%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, AMPH is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
AMPH vs EMBCV Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AMPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AMPH vs DVAX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AMPH's ROE is +0.10%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AMPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AMPH vs ANIP Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ANIP trades at $72.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ANIP's P/E ratio is 9.10. In terms of profitability, AMPH's ROE is +0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AMPH is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AMPH vs ETON Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ETON trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ETON's P/E ratio is 155.74. In terms of profitability, AMPH's ROE is +0.10%, compared to ETON's ROE of +0.40%. Regarding short-term risk, AMPH is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AMPH vs TARO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TARO's P/E ratio is 30.05. In terms of profitability, AMPH's ROE is +0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AMPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AMPH vs PAHC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PAHC trades at $35.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PAHC's P/E ratio is 12.18. In terms of profitability, AMPH's ROE is +0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AMPH is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
AMPH vs CRON Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CRON's P/E ratio is 17.46. In terms of profitability, AMPH's ROE is +0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AMPH is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CRON's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AMPH vs HROW Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while HROW trades at $31.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas HROW's P/E ratio is -31.92. In terms of profitability, AMPH's ROE is +0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, AMPH is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AMPH vs PCRX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PCRX trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PCRX's P/E ratio is 9.77. In terms of profitability, AMPH's ROE is +0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AMPH is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AMPH vs PETQ Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AMPH's ROE is +0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AMPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AMPH vs COLL Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, COLL has a market cap of 734M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while COLL trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas COLL's P/E ratio is 2.84. In terms of profitability, AMPH's ROE is +0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AMPH is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AMPH vs IRWD Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while IRWD trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas IRWD's P/E ratio is 5.28. In terms of profitability, AMPH's ROE is +0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AMPH is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AMPH vs AQST Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, AQST has a market cap of 596M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while AQST trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas AQST's P/E ratio is -7.31. In terms of profitability, AMPH's ROE is +0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, AMPH is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AMPH vs BDSI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AMPH's ROE is +0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AMPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
AMPH vs EVO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while EVO trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas EVO's P/E ratio is -2.25. In terms of profitability, AMPH's ROE is +0.10%, compared to EVO's ROE of -0.27%. Regarding short-term risk, AMPH is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
AMPH vs GLAS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while GLAS trades at $6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas GLAS's P/E ratio is -12.22. In terms of profitability, AMPH's ROE is +0.10%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, AMPH is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
AMPH vs EOLS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while EOLS trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas EOLS's P/E ratio is -25.21. In terms of profitability, AMPH's ROE is +0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AMPH is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
AMPH vs KMDA Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while KMDA trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas KMDA's P/E ratio is 22.68. In terms of profitability, AMPH's ROE is +0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AMPH is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AMPH vs TKNO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TKNO trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TKNO's P/E ratio is -29.68. In terms of profitability, AMPH's ROE is +0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AMPH is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AMPH vs TLRY Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TLRY trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TLRY's P/E ratio is -3.71. In terms of profitability, AMPH's ROE is +0.10%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, AMPH is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AMPH vs CGC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CGC's P/E ratio is -2.07. In terms of profitability, AMPH's ROE is +0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, AMPH is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
AMPH vs EBS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, EBS has a market cap of 354M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while EBS trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas EBS's P/E ratio is 4.76. In terms of profitability, AMPH's ROE is +0.10%, compared to EBS's ROE of -0.36%. Regarding short-term risk, AMPH is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AMPH vs ALIM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AMPH's ROE is +0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AMPH is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
AMPH vs LNDC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AMPH's ROE is +0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AMPH is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AMPH vs ACB Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ACB trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ACB's P/E ratio is -2.95. In terms of profitability, AMPH's ROE is +0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AMPH is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AMPH vs SIGA Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SIGA trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SIGA's P/E ratio is 12.81. In terms of profitability, AMPH's ROE is +0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AMPH is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AMPH vs LFCR Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while LFCR trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas LFCR's P/E ratio is -5.13. In terms of profitability, AMPH's ROE is +0.10%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, AMPH is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
AMPH vs TYHT Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AMPH's ROE is +0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AMPH is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AMPH vs CRDL Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CRDL's P/E ratio is -6.73. In terms of profitability, AMPH's ROE is +0.10%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AMPH is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AMPH vs ORGO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ORGO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ORGO's P/E ratio is 46.00. In terms of profitability, AMPH's ROE is +0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, AMPH is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AMPH vs REPH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas REPH's P/E ratio is -8.04. In terms of profitability, AMPH's ROE is +0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AMPH is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
AMPH vs DERM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while DERM trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas DERM's P/E ratio is -29.23. In terms of profitability, AMPH's ROE is +0.10%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AMPH is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AMPH vs THTX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas THTX's P/E ratio is -28.83. In terms of profitability, AMPH's ROE is +0.10%, compared to THTX's ROE of +0.36%. Regarding short-term risk, AMPH is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
AMPH vs OGI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while OGI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas OGI's P/E ratio is 2.44. In terms of profitability, AMPH's ROE is +0.10%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AMPH is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AMPH vs ASRT Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AMPH's ROE is +0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AMPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AMPH vs SCTL Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AMPH's ROE is +0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AMPH is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AMPH vs CPIX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CPIX trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CPIX's P/E ratio is -19.30. In terms of profitability, AMPH's ROE is +0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AMPH is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
AMPH vs PROC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PROC's P/E ratio is 1.53. In terms of profitability, AMPH's ROE is +0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AMPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AMPH vs OPTN Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AMPH's ROE is +0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AMPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AMPH vs ZOM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AMPH's ROE is +0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AMPH is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
AMPH vs GRVI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AMPH's ROE is +0.10%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, AMPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
AMPH vs BGM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while BGM trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas BGM's P/E ratio is -1.46. In terms of profitability, AMPH's ROE is +0.10%, compared to BGM's ROE of -0.05%. Regarding short-term risk, AMPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AMPH vs ZYNE Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AMPH's ROE is +0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AMPH is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AMPH vs SSIC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AMPH's ROE is +0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AMPH is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
AMPH vs TLPH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TLPH trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TLPH's P/E ratio is -3.84. In terms of profitability, AMPH's ROE is +0.10%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AMPH vs ZYBT Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ZYBT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, AMPH's ROE is +0.10%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, AMPH is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AMPH vs VLNS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AMPH's ROE is +0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, AMPH is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
AMPH vs INCR Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while INCR trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas INCR's P/E ratio is -4.92. In terms of profitability, AMPH's ROE is +0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AMPH is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
AMPH vs DRRX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AMPH's ROE is +0.10%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, AMPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AMPH vs JUPW Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AMPH's ROE is +0.10%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AMPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AMPH vs QLI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas QLI's P/E ratio is -4.92. In terms of profitability, AMPH's ROE is +0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AMPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AMPH vs RMTI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while RMTI trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas RMTI's P/E ratio is -6.44. In terms of profitability, AMPH's ROE is +0.10%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AMPH is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
AMPH vs HEXO Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AMPH's ROE is +0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AMPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AMPH vs CPHI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CPHI trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CPHI's P/E ratio is -1.69. In terms of profitability, AMPH's ROE is +0.10%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AMPH is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AMPH vs TXMD Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while TXMD trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas TXMD's P/E ratio is 106.47. In terms of profitability, AMPH's ROE is +0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AMPH is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AMPH vs CYTH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AMPH's ROE is +0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AMPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AMPH vs AYTU Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while AYTU trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas AYTU's P/E ratio is -0.47. In terms of profitability, AMPH's ROE is +0.10%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, AMPH is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AMPH vs EVOK Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AMPH's ROE is +0.10%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, AMPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AMPH vs OPTH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while OPTH trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas OPTH's P/E ratio is -3.37. In terms of profitability, AMPH's ROE is +0.10%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AMPH is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AMPH vs ACRX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AMPH's ROE is +0.10%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
AMPH vs CABR Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while CABR trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas CABR's P/E ratio is -1.59. In terms of profitability, AMPH's ROE is +0.10%, compared to CABR's ROE of -3.86%. Regarding short-term risk, AMPH is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AMPH vs AGRX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AMPH's ROE is +0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AMPH is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AMPH vs NLTX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AMPH's ROE is +0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AMPH is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AMPH vs LCI Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas LCI's P/E ratio is -0.04. In terms of profitability, AMPH's ROE is +0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AMPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AMPH vs ADMP Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AMPH's ROE is +0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AMPH is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AMPH vs GELS Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while GELS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas GELS's P/E ratio is -1.09. In terms of profitability, AMPH's ROE is +0.10%, compared to GELS's ROE of -0.25%. Regarding short-term risk, AMPH is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
AMPH vs YCBD Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while YCBD trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas YCBD's P/E ratio is -1.14. In terms of profitability, AMPH's ROE is +0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AMPH is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
AMPH vs MNK Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas MNK's P/E ratio is -0.44. In terms of profitability, AMPH's ROE is +0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, AMPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AMPH vs FLGC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AMPH's ROE is +0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AMPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AMPH vs UPC Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while UPC trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas UPC's P/E ratio is -0.61. In terms of profitability, AMPH's ROE is +0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AMPH is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AMPH vs PLXP Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AMPH's ROE is +0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AMPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
AMPH vs INM Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while INM trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas INM's P/E ratio is -0.25. In terms of profitability, AMPH's ROE is +0.10%, compared to INM's ROE of -1.35%. Regarding short-term risk, AMPH is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AMPH vs SHPH Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SHPH trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SHPH's P/E ratio is -0.19. In terms of profitability, AMPH's ROE is +0.10%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, AMPH is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
AMPH vs ATNX Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AMPH's ROE is +0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AMPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AMPH vs SNOA Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while SNOA trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas SNOA's P/E ratio is -1.14. In terms of profitability, AMPH's ROE is +0.10%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, AMPH is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
AMPH vs PROCW Comparison September 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, AMPH is priced at $26.86 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 9.35, whereas PROCW's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.10%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, AMPH is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PROCW's competition here